Shares of Amedisys Inc. (NASDAQ:AMED) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $55.09 and last traded at $54.85, with a volume of 136,875 shares changing hands. The stock had previously closed at $53.55.

AMED has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Friday, May 6th. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $56.00 price target on shares of Amedisys in a research note on Wednesday, May 4th. Stephens started coverage on shares of Amedisys in a research note on Thursday, June 16th. They set an “equal weight” rating and a $55.00 target price on the stock. Robert W. Baird restated a “hold” rating on shares of Amedisys in a research note on Monday, May 16th. Finally, Mizuho restated a “buy” rating and set a $57.00 target price (up from $49.00) on shares of Amedisys in a research note on Monday, April 11th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $52.00.

The firm has a market capitalization of $1.84 billion and a PE ratio of 47.62. The stock’s 50-day moving average price is $51.23 and its 200 day moving average price is $46.02.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. During the same period in the previous year, the business posted $0.30 earnings per share. The business earned $348.80 million during the quarter, compared to analyst estimates of $337.07 million. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. On average, analysts anticipate that Amedisys Inc. will post $1.74 EPS for the current fiscal year.

In other Amedisys news, insider Scott G. Ginn sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $51.62, for a total value of $309,720.00. Following the sale, the insider now directly owns 48,009 shares of the company’s stock, valued at approximately $2,478,224.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bruce D. Perkins purchased 1,000 shares of the firm’s stock in a transaction on Friday, May 13th. The stock was acquired at an average cost of $50.21 per share, for a total transaction of $50,210.00. Following the completion of the purchase, the director now owns 10,354 shares in the company, valued at approximately $519,874.34. The disclosure for this purchase can be found here.

A number of hedge funds have modified their holdings of the company. BlackRock Advisors LLC raised its stake in shares of Amedisys by 5.1% in the fourth quarter. BlackRock Advisors LLC now owns 931,832 shares of the company’s stock worth $36,640,000 after buying an additional 44,867 shares during the last quarter. TrimTabs Asset Management LLC purchased a new position in Amedisys during the fourth quarter valued at $2,169,000. Trexquant Investment LP purchased a new position in Amedisys during the fourth quarter valued at $1,031,000. Systematic Financial Management LP raised its position in Amedisys by 207.5% in the fourth quarter. Systematic Financial Management LP now owns 321,583 shares of the company’s stock valued at $12,644,000 after buying an additional 217,008 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Amedisys by 4.7% in the fourth quarter. Principal Financial Group Inc. now owns 186,997 shares of the company’s stock valued at $7,353,000 after buying an additional 8,329 shares in the last quarter.

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.